Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: The Atherosclerosis Risk in Communities (ARIC) study

Annals of Internal Medicine

Volumn 133, Issue 2, 2000, Pages 81-91

  Saito, Isao ^a   Folsom, Aaron R ^b   Brancati, Frederick L ^c   Duncan, Bruce B ^d,f   Chambless, Lloyd E ^e,g   McGovern, Paul G ^b  

^a OITA UNIVERSITY   (Japan)

^b UNIVERSITY OF MINNESOTA   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f Universidade Federal de Rio Grande   (Brazil)

^g IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING TEST; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; HUMAN; ISCHEMIC HEART DISEASE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

EID: 0034682644     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-133-2-200007180-00007     Document Type: Article

References (68)

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434-44.
2. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham Study. Circulation. 1979;59:8-13.
3. Vilbergsson S, Sigurdsson G, Sigvaldason H, Sigfusson N. Coronary heart disease mortality amongst non-insulin-dependent diabetic subjects in Iceland: the independent effect ot diabetes. The Reykjavik Study 17-year follow up. J Intern Med. 1998;244:309-16.
4. Reaven GM. Banting Lecture 1988. Rule of insulin resistance in human disease. Diabetes. 1988;37:1595-607.
5. Getz GS. Report on the workshop on diabetes and mechanisms of atherogenesis. September 17th and 18th, Bethesda, Maryland. Arterioscler Thromb. 1993;13:459-64.
6. Haffner SM, Miettinen H. Insulin resistance implications for type II diabetes mellitus and coronary heart disease. Am J Med. 1997;103:152-62.
7. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998;21:518-24.
8. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA. 1999;281:1291-7.
9. Grundy SM, Benjamin U, Burke GL, Chait A, Eckel RH, Howard BV, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999;100:1134-46.
10. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study. BMJ. 1998; 316:823-8.
11. Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K. 5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects. Circulation. 1990;82: 27-36.
12. Lehto S, Ronnemaa T, Haffner SM, Pyorala K, Kallio V, Laasko M. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes. 1997;46:1354-9.
13. Laakso M, Lehto S, Penttila I, Pyorala K. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation. 1993;88(4 Pt 1):1421-30.
14. Vaccaro O, Stamler J, Neaton JD. Sixteen-year coronary mortality in black and white men with diabetes screened for the Multiple Risk Factor Intervention Trial (MRFIT). Int J Epidemiol. 1998;27:636-41.
15. Standl E, Balletshofer B, Dahl B, Weichenhain B, Stiegler H, Hormann A, et al. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. Diabetologia. 1996;39:1540-5.
16. Juhan-Vague I, Alessi MC, Vague P. Thrombogenic and fibrinolytic factors and cardio-vascular risk in non-insulin-dependent diabetes mellitus. Ann Med. 1996;28:371-80.
17. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC Investigators. Am J Epidemiol. 1989;129:687-702.
18. Folsom AR, Szklo M, Stevens J, Liao F, Smith R, Eckfeldt JH. A prospective study of coronary heart disease in relation to fasting insulin, glucose, and diabetes. The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care. 1997;20:935-42.
19. Jackson R, Chambless LE, Yang K, Byrne T, Watson R, Folsom A, et al. Differences between respondents and nonrespondents in a multicenter community-based study vary by gender and ethnicity. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. J Clin Epidemiol. 1996; 49:1441-6.
20. Eckfeldt JH, Chambless LE, Shen YL. Short-term, within-person variability in clinical chemistry test results. Experience from the Atherosclerosis Risk in Communities Study. Arch Pathol Lab Med. 1994;118:496-500.
21. Gindler EM, Heth DA. Colorimetric determination with bound "Calmagite" of magnesium in human blood serum [Abstract]. Clin Chem. 1971; 17:662.
22. Doumas BT, Watson WA, Biggs HG. Albumin standards and the measurement of serum albumin with bromcresol green. Clin Chim Acta. 1971;31:87-96.
23. Siedel J, Hagele EO, Ziegenhorn J, Wahlefeld AW. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem. 1983;29:1075-80.
24. Nagele U, Hagele EO, Sauer G, Wiedemann E, Lehmann P, Wahlefeld AW, et al. Reagent for the enzymatic determination of serum total triglycerides with improved lipolytic efficiency. J Clin Chem Clin Biochem. 1984;22:165-74.
25. 2+ precipitation [Abstract]. Clin Chem. 1982;28:1574.
26. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
27. Patsch W, Brown SA, Morrisett JD, Gotto AM Jr, Patsch JR. A dual-precipitation method evaluated for measurement of cholesterol in high-density lipoprotein subfractions HDL2 and HDL3 in human plasma. Clin Chem. 1989;35:265-70.
28. Schonfeld G, Pfleger B. The structure of human high density lipoprotein and the levels of apolipoprotein A-I in plasma as determined by radioimmunoassay. J Clin Invest. 1974;54:236-46.
29. Maciejko JJ, Mao SJ. Radioimmunoassay of apolipoprotein A-I. Application of non-ionic detergent (Tween-20) and solid-phase staphylococcus. Clin Chem. 1982;28:199-204,
30. Schonfeld G, Lees RS, George PK, Pfleger B. Assay of total plasma apolipoprotein B concentration in human subjects. J Clin Invest. 1974;53: 1458-67.
31. Gaubatz JW, Ghanem KI, Guevara J Jr, Nava ML, Patsch W, Morrisett JD. Polymorphic forms of human apolipoprotein[a]: inheritance and relationship of their molecular weights to plasma levels of lipoprotein[a]. J Lipid Res. 1990;31:603-13.
32. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol. 1957;17:237-46.
33. Baecke JA, Burema J, Frijters JE. A short questionnaire for the measurement of habitual physical activity in epidemiological studies. Am J Clin Nutr. 1982;36:936-42.
34. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183-97.
35. White AD, Folsom AR, Chambless LE, Sharrett AR, Yang K, Conwill D, et al. Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years' experience. J Clin Epidemiol. 1996;49:223-33,
36. Prineas RJ, Blackburn H, Crow RS. The Minnesota Code Manual of Electrocardiographic Findings: Standards and Procedures for Measurement and Classification. Boston: Wright-PSG; 1982.
37. Rautaharju PM, Warren JW, Jain U, Wolf HK, Nielsen CL. Cardiac infarction injury score: an electrocardiographic coding scheme for ischemic heart disease. Circulation. 1981;64:249-56.
38. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 1997;96:1102-8.
39. Schreiner PJ, Heiss G, Tyroler HA, Morrisett JD, Davis CE, Smith R. Race and gender differences in the association of Lp(a) with carotid artery wall thickness. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vase Biol. 1996;16:471-8.
40. Liao F, Folsom AR, Brancati FL. Is low magnesium concentration a risk factor for coronary heart disease? The Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 1998;136:480-90.
41. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-53.
42. Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JP, et al. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care. 1995;18:1113-23.
43. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998;279:1477-82.
44. Kannel WB, D'Agostino RB, Wilson PW, Belanger AJ, Gagnon DR. Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J. 1990;120:672-6.
45. Missov RM, Stolk RP, van der Bom JG, Hofman A, Bots ML, Pols HA, et al. Plasma fibrinogen in NIDDM: the Rotterdam Study. Diabetes Care. 1996;19:157-9.
46. De Feo P, Volpi E, Lucidi P, Cruciani G, Reboldi G, Siepi D, et al. Physiological increments in plasma insulin concentrations have selective and different effects on synthesis of hepatic proteins in normal humans. Diabetes. 1993;42:995-1002.
47. Conlan MG, Folsom AR, Finch A, Davis CE, Sorlie P, Marcucci G, et al. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost. 1993;70:380-5.
48. Facchini F, Hollenbeck CB, Chen YN, Chen YD, Reaven GM. Demonstration of a relationship between white blood cell count, insulin resistance, and several risk factors for coronary heart disease in women. J Intern Med. 1992;232:267-72.
49. Bruno G, Cavallo-Perin P, Bargero G, Borra M, D'Errico N, Pagano G. Association of fibrinogen with glycemic control and albumin excretion rate in patients with non-insulin-independent diabetes mellitus. Ann Intern Med. 1996;125:653-7.
50. Stehouwer CD, Nauta JJ, Zeldenrust GC, Hackeng WH, Donker AJ, den Ottolander GJ. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet. 1992;340:319-23.
51. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984;310:356-60.
52. Mattock MB, Barnes DJ, Viberti G, Keen H, Burt D, Hughes JM, et al. Microalbuminuria and coronary heart disease in NIDDM: an incident study. Diabetes. 1998;47:1786-92.
53. Ceriello A, Pirisi M, Giacomello R, Stel G, Falleti E, Motz E, et al. Fibrinogen plasma levels as a marker of thrombin activation: new insights on the role of fibrinogen as cardiovascular risk factor. Thromb Haemost. 1994; 71:593-5.
54. Kessler L, Wiesel ML, Attali P, Mossard JM, Cazenave JP, Pinget M. Von Willebrand factor in diabetic angiopathy. Diabetes Metab. 1998; 24:327-36.
55. Duncan BB, Schmidt MI, Offenbacher S, Wu KK, Savage PJ, Heiss G. Factor VIII and other hemostasis variables are related to incident diabetes in adults. The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care. 1999;22:767-72.
56. Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet. 1999;353:1649-52.
57. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia. 1998;41:1241-8.
58. Stern MP. Diabetes and cardiovascular disease. The "common soil" hypothesis. Diabetes. 1995;44:369-74.
59. Jarrett RJ, Shipley MJ. Type 2 (non-insulin-dependent) diabetes mellitus and cardiovascular disease - putative association via common antecedents; further evidence from the Whitehall Study. Diabetologia. 1988;31: 737-40.
60. DeStefano F, Newman J. Comparison of coronary heart disease mortality risk between black and white people with diabetes. Ethn Dis. 1993;3: 145-51.
61. Vaccaro O, Stamler J, Neaton JD. Sixteen-year coronary mortality in black and white men with diabetes screened for the Multiple Risk Factor Intervention Trial (MRFIT). Int J Epidemiol. 1998;27:636-41.
62. Ethnicity and cardiovascular disease. The incidence of myocardial infarction in white, South Asian, and Afro-Caribbean patients with type 2 diabetes (U.K. Prospective Diabetes Study 32). Diabetes Care. 1998;21:1271-7.
63. Rosamond WD, Chambless LE, Folsom AR, Cooper LS, Conwill DE, Clegg L, et al. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N Engl J Med. 1998;339:861-7.
64. Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies. The DECODE-study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis of Diagnostic Criteria in Europe. Diabetologia. 1999;42:647-54.
65. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic Criteria in Europe. Lancet. 1999;354:617-21.
66. Niskanen LK, Tuomi T, Karjalainen J, Groop LC, Uusitupa MI. GAD antibodies in NIDDM. Ten-year follow-up from the diagnosis. Diabetes Care. 1995;18:1557-65.
67. Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR, et al. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet. 1997;350:1288-93.
68. Yudkin JS. Assessing the evidence on aspirin in diabetes mellitus. Gemini or Libra; lumping or splitting; surrogate or hard; low or high; interventionist or nihilist. Diabetologia. 1996;39:1407-8.